Campbell & Co Investment Adviser’s Viking Therapeutics VKTX Stock Holding History

Campbell & Co Investment Adviser’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-4,095	Closed	-$336K	–	1373
2024 Q1	$336K	Sell	4,095 -25,183	-86%	-$1.12M	0.03%	862
2023 Q4	$545K	Buy	+29,278	New	+$383K	0.05%	668
2023 Q3	–	Sell	-18,476	Closed	-$299K	–	1211
2023 Q2	$299K	Buy	+18,476	New	+$387K	0.05%	666
2022 Q1	–	Sell	-53,600	Closed	-$247K	–	925
2021 Q4	$247K	Buy	+53,600	New	+$300K	0.08%	444

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Campbell & Co Investment Adviser's VKTX Position: Q2 2024 in Review

Campbell & Co Investment Adviser sold out of Viking Therapeutics (VKTX) in Q2 2024, closing a stake of 4,095 shares — an estimated $336K sold.

Campbell & Co Investment Adviser first reported a position in VKTX in Q4 2021 and held it in 4 quarters. The position peaked at $545K in Q4 2023. 387 funds tracked by Wall St. Rank hold VKTX as of Q2 2024.

Campbell & Co Investment Adviser reported no remaining Viking Therapeutics position as of Q2 2024 after selling out during the quarter.
Campbell & Co Investment Adviser sold 4,095 Viking Therapeutics shares in Q2 2024, an estimated $336K.
Campbell & Co Investment Adviser first reported a position in Viking Therapeutics in Q4 2021 and held it in 4 quarters.
Campbell & Co Investment Adviser's Viking Therapeutics position peaked at $545K in Q4 2023.
387 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2024.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2024, filed 13 Aug 2024.